Choosing the best treatment for disease

The diagnosis has come in, and it's not good. Worse, the patient has to choose from treatment options that are sometimes contradictory and risky.

None of them promises complete success. How do patients make an informed decision, choosing the very best treatment for their own healthcare?

These questions are addressed in the September/October 2007 special issue of Medical Decision Making (MDM) about the future of shared decision-making. The issue, published on behalf of the Society for Medical Decision Making by SAGE features new research articles, systematic reviews of the state of the science, and other perspectives. Some of the articles summarize past research on decision aids and communicating about risk, others describe new approaches and best practices for assessing and conveying risk information, and several suggest new paths for future research.

“For more than two decades, Medical Decision Making has published research about patients choosing therapies that are consistent with their preferences,” writes MDM editor Mark Helfand in his editorial highlighting the issue's articles. “Today, all sectors of the health care system—providers, payers, advocacy and consumer groups, industry, the lay press, and government—recognize that improvements in decision making are urgently needed and the research and recommendations described in this issue address practical ways to improve decision-making processes.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research suggests no need for yellow fever vaccine booster after initial dose